Laimonas Griskevicius
Overview
Explore the profile of Laimonas Griskevicius including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reuvekamp T, Ngai L, den Hartog D, Carbaat-Ham J, Fayed M, Scholten W, et al.
Leukemia
. 2025 Feb;
PMID: 40016301
No abstract available.
2.
Taalas T, Oskarsson T, Heyman M, Lund B, Lepik K, Vaitkeviciene G, et al.
Haematologica
. 2025 Feb;
PMID: 39973352
Age and sex have historically been associated with differences in acute lymphoblastic leukemia (ALL) survival. In the NOPHO ALL2008 trial, patients aged 1-45 years with BCR::ABL1-negative B-precursor and Tcell ALL...
3.
Petruskeviciute A, Simuliunaite U, Polanco C, Rojas B, Kuras S, Valatkaite-Rakstiene B, et al.
Stem Cell Res
. 2024 Dec;
82():103628.
PMID: 39721357
Fluorescent protein-based Genetically Encoded Voltage Indicators (GEVI) offer a remarkable system for high-throughput screening of membrane potential phenotypes. The GEVI MARINA is a derivative from ArcLight, which conversely to ArcLight...
4.
Efficace F, Kicinski M, Coens C, Suciu S, van der Velden W, Noppeney R, et al.
Blood
. 2024 May;
144(5):541-551.
PMID: 38717861
We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC)....
5.
Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji R, Griskevicius L, et al.
Bone Marrow Transplant
. 2024 Apr;
59(7):1012-1021.
PMID: 38615143
Post-transplant cyclophosphamide plus calcineurin inhibitor (CNI)(tacrolimus or cyclosporine A) plus mycophenolate mofetil (PTCy/TAC or CSA/MMF) and anti-thymocyte globulin plus CNI (tacrolimus or cyclosporine A) plus methotrexate (ATG/TAC or CSA/MTX) are...
6.
Zucenka A, Griskevicius L
Br J Haematol
. 2024 Jan;
204(4):1227-1231.
PMID: 38291741
We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax,...
7.
Dam M, Centanni M, Friberg L, Centanni D, Karlsson M, Stensig Lynggaard L, et al.
Leukemia
. 2024 Jan;
38(4):712-719.
PMID: 38287133
Asparaginase is an essential component of acute lymphoblastic leukemia (ALL) therapy, yet its associated toxicities often lead to treatment discontinuation, increasing the risk of relapse. Hypersensitivity reactions include clinical allergies,...
8.
Lubbert M, Wijermans P, Kicinski M, Chantepie S, van der Velden W, Noppeney R, et al.
Lancet Haematol
. 2023 Nov;
10(11):e879-e889.
PMID: 37914482
Background: Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy...
9.
Kevlicius L, Sablauskas K, Maneikis K, Juozapaite D, Ringeleviciute U, Vaitekenaite V, et al.
Br J Haematol
. 2023 Oct;
204(2):497-506.
PMID: 37786970
Information regarding the protective anti-SARS-CoV-2 antibody levels and the effectiveness of the mRNA vaccines against the Omicron variant in patients with haematological malignancies is limited. We prospectively followed two times...
10.
Orti G, Gras L, Koster L, Kulagin A, Byrne J, Apperley J, et al.
Transplant Cell Ther
. 2023 Oct;
30(1):93.e1-93.e12.
PMID: 37783337
Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor (MMRD) remain unknown. We...